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Abstract
Propionic acidemia (PA, MIM 232000 and 232050) is caused by a deficiency of mitochondrial biotin-dependent propionyl-CoA
carboxylase (PCC, EC 6.4.1.3), a heteropolymeric enzyme composed of a and h subunits, which are encoded by the PCCA and PCCB genes,
respectively. The PCCA protein (a subunit) is responsible for the formation of carboxybiotin upon hydrolysis of ATP and contains a C-
terminal biotin-binding domain and a biotin carboxylase domain, defined by homology with other biotin-dependent carboxylases, some of
them characterized structurally. More than 24 mutations have been found in the PCCA gene in patients with PA, among them 14 missense
mutations and one in-frame deletion, for which the precise molecular effect is unknown. In this study, we have established the pathogenicity
of 11 PCCA mutations (10 missense and an in-frame deletion) by expression studies in deficient fibroblasts and in a cell-free in vitro system,
and analyzed the effect of each mutation on PCC activity, protein stability and domain structure. The results show that most mutant proteins
show an increased turnover and are functionally deficient, suggesting that the structural alterations they cause are incompatible with normal
assembly to produce a stable, functional PCC oligomer. These results are discussed in the context of the genotype–phenotype correlations in
PCCA-deficient PA patients.
D 2002 Elsevier Science B.V. All rights reserved.
Keywords: Propionic acidemia; PCCA; Mutation; Expression analysis; Genotype–phenotype correlation
1. Introduction
Propionic acidemia (PA, MIM 232000 and 232050)
results from a genetic deficiency of propionyl-CoA carbox-
ylase (PCC, EC 6.4.1.3), a mitochondrial, biotin-dependent
enzyme involved in the degradation of branched-chain
amino acids, odd-number chain length fatty acids and other
metabolites [1]. The enzyme is composed of two types of
subunits, a and h, encoded by the genes PCCA and PCCB,
respectively. Both subunits are synthesized as larger pre-
cursors with mitochondrial leader peptides at the amino
terminus [2].
The cDNAs for the a and h subunits have been cloned
[3–5] and the structure of the genes elucidated [6,7]. The
PCCA gene comprises 24 exons and the translation initia-
tion codon has recently been redefined 75 nucleotides
upstream of the originally reported, which accounts for 25
extra amino acids in the amino terminal region of the
protein, although the mature protein is predicted to be the
same [6]. The PCCB gene contains 15 exons [7].
Mutations in either gene cause PA [8], which in most
affected patients presents as a life-threatening ketoacidosis
during neonatal period, although in other cases there is a late
onset with milder symptoms. Up to date, no clear correlation
has been found between the degree of enzyme deficiency in
patients’ fibroblasts, the clinical outcome and the genotype
[9]. Recently, an animal model of PA was generated by
creating PCCA knockout mice and also a transgenic strain
expressing low levels of PCCA exclusively in the liver, both
useful for the further understanding of PA pathogenesis and
to test successful therapies of the disease [10].
PCC catalyses the ATP-dependent carboxylation of
propionyl-CoA to D-methylmalonyl CoA. In the first
half-reaction, catalysed by the a subunit, bicarbonate is
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transferred to biotin upon hydrolysis of ATP to form
carboxybiotin. The h subunit is responsible for the sub-
sequent transfer of the carboxyl group of carboxybiotin to
propionyl-CoA. In the a subunit, two functional domains
have been identified by homology with other biotin-
dependent carboxylases. They include a putative biotin
carboxylase domain containing the ATP and bicarbonate-
binding sites, and a C-terminal biotin-binding domain
with the conserved A-M-K-M motif [11,12]. The homol-
ogous proteins biotin carboxylase and biotin carboxyl
carrier protein (BCCP), subunits of acetyl-coA carboxy-
lase from Escherichia coli, have been crystallized recently
[13,14], providing a structural framework to study the
effect of PCCA mutations.
Several expression studies have addressed the effect of
pccb gene mutations on assembly and activity of the PCC
enzyme [15–19]. However, extensive information on the
effect of missense pcca mutations is still lacking, with only
two reports describing defective biotinylation for the G668R
mutation [12] and a reduced intramitochondrial stability of
M373K [20]. In the present study, we report the expression
of 11 PCCA mutations (10 missense and 1 in-frame dele-
tion) in deficient fibroblasts and in a cell-free system with
coupled import into rat liver mitochondria, with the aim of
gaining further insight into the structure–function relation-
ship of human PCCA protein and into the genotype–
phenotype correlations in PA.
2. Methods
Primary fibroblasts from a PCCA-deficient patient carry-
ing IVS21 + 3del4 mutation in homozygous fashion, were
stably transformed by lipofection followed by phenotypic
selection using the T22 plasmid which contains SV40 DNA
sequences (kindly supplied by Dr. P.H. Gallimore) [21].
Previous studies had shown the absence of functional PCCA
protein and undetectable PCC activity in the primary fibro-
blasts [22], which was also confirmed in the transformed
cells. These cells were used in the transfection experiments
with the expression vectors pCMVA45-12 and pRcCMVB52
(provided by Dr. Leclerc and Prof. Gravel), which code for
the PCCA and PCCB cDNAs, respectively. Vectors contain-
ing the desired mutations were prepared by PCRmutagenesis
using the Quickchange mutagenesis kit (Stratagene). PCCA
mutations are named according to the recently defined novel
initiation codon [6]. For the delEx21 mutation, caused by the
effect of different mutations in exon 21 splice acceptor and
donor sites [22], two oligos: 5V-GCACTCAGAGGACTGTC-
CAGTACAAGGTGAATA TCTTAAC-3Vand its comple-
mentary were used to delete nucleotides 1846–1899 com-
prising exon 21 from PCCA cDNA. The resulting cDNA
codes for a PCCA protein lacking 18 amino acids (residues
616–634). For each of the other point mutations, two mu-
tagenic oligos, sense and complementary antisense, were
designed with 13–15 bases of correct sequence on both sides
of the mutation. Sequence analysis confirmed the identity of
the mutant clones.
Transfection was achieved by lipofection using Gene
Porterk (Gene Therapy System) as transfection reagent
and following the manufacturer’s recommendations. 0.6
106 cells were plated in 25-cm2 flasks and transfected with
30 Al of lipid and a mixture of DNA containing 2 Ag of each
PCCA (wild-type or mutant) and PCCB constructs in serum-
free medium. After 5 h incubation at 37 jC, the medium
was replaced by MEM with 10% fetal calf serum. Cells
were harvested 72 h after transfection and PCC activity
assayed [23].
For the detection of biotin-bound proteins, transfected
fibroblasts were harvested by trypsinization, resuspended in
sucrose buffer (0.25 M sucrose, 10 mM Tris–HCl pH 7.4,
EDTA 2 mM, PMSF 0.2 mM) and disrupted with a Teflon
Potter homogenizer. Mitochondria were isolated by differ-
ential centrifugation at 4 jC [24], suspended in sucrose
buffer and protein concentration determined by the Bradford
assay. Equal amounts of total protein (100 Ag) from each
sample were loaded on a denaturing 6% polyacrylamide gel.
After electrophoresis, proteins were transferred to PVDF
membranes (Immobilonk-P, Millipore) and the biotin-con-
taining proteins were detected with an avidin alkaline
phosphatase conjugate (Pierce), using NBT/BCIP (Pierce)
as alkaline phosphatase substrate for color development.
For in vitro transcription and translation, we used the
pGEM-PCCA vector [20]. Mutations were introduced in the
cloned PCCA cDNA using the Quickchange mutagenesis kit
(Stratagene). One microgram of the resulting plasmids,
normal or mutant, were used with the TnT Coupled Tran-
scription/Translation kit (Promega) in the presence of [35S]-
Methionine+[35S]-Cysteine (Promix L-[35S] in vitro cell
labelling mix, Amersham Pharmacia Biotech) for 60 min
at 28 jC, following the manufacturer’s protocol. Rat liver
mitochondria were prepared according to previously
described methods [25] and were used at 30–40 mg/ml in
HMS buffer (2 mM HEPES, pH 7.4, 220 mM D-mannitol,
70 mM sucrose). Mitochondrial import was carried out with
equal volumes of translation product and mitochondria,
incubated at 30 jC for 60 min. The mitochondrial pellet
was then separated from the supernatant by centrifugation,
washed twice with HMS buffer, resuspended in the same
buffer and further incubated at 37 jC, removing aliquots at
different time points up to 24 h. After boiling in SDS buffer,
samples were subjected to SDS-PAGE electrophoresis. The
radioactive proteins were visualized after SDS-PAGE and
fluorography. The bands were quantitated by laser densi-
tometry.
Structural analysis of PCCA mutations was performed
using homologous crystallized proteins available in the PDB
database. The biotin carboxylase subunit of E. coli acetyl-
CoA carboxylase (PDB coordinates 1DV2) [13] was used as
a template for the biotin carboxylase domain of PCC (amino
acids 64–513). Both the E. coli BCCP (PDB coordinates
1BDO) [14] and the 1.3 S subunit of the Propionibacterium
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shermanii transcarboxylase complex (PDB coordinates
1DCZ) [26] were used as templates for the biotinylation
domain of PCCA (amino acids 621–728). Models were dis-
played using WebLab Viewer software (Molecular Simula-
tions).
3. Results
3.1. Transient transfection in PCCA-deficient fibroblasts
The introduction of wild-type PCCA cDNA in the
deficient fibroblasts resulted in a partial restoration of
PCC activity (580F 171 pmol/min/mg protein). However,
when both wild-type PCCA and PCCB cDNAs were
cotransfected, enzyme activity levels were higher than for
control transformed fibroblasts (3432F 232.9 pmol/min/mg
protein versus 1123F 455 pmol/min/mg protein, respec-
tively) (Table 1). This demonstrates that both subunits have
been efficiently expressed, imported into mitochondria and
assembled and that coordinated overexpression of both
subunits is necessary to achieve maximal enzyme activity.
A total of 11 PCCA mutations were analyzed by transient
transfection in PCCA-deficient fibroblasts, with cotransfec-
tion of wild-type PCCB. They include 10 missense muta-
tions (A75P, R77W, A138T, I164T, M229K, D368G,
M373K, G379V, G631R and G668R) and 1 in-frame
deletion of 18 amino acids corresponding to exon 21
(delEx21), skipped in the mRNA as a consequence of
different mutations in the splice donor and acceptor sites
[22]. In all cases, PCC activity was clearly diminished
compared to the results obtained with wild-type PCCA,
demonstrating the pathogenicity of the mutations tested.
Most mutant proteins resulted in < 5% residual activity;
only those carrying A75P, A138T and I164T substitutions
showed a low–intermediate PCC activity (26.7%, 9.4% and
16%, see Table 1).
Examination of the pattern of biotinylated mitochondrial
proteins in transfected fibroblasts demonstrated similar
amounts of a-PCC subunit for wild type and all mutations
tested except for G668R (Fig. 1). No biotinylated G668R
protein is detected, in accordance with previous reports
showing it is defective in biotin binding [27]. A slightly
smaller molecular weight is observed for the delEx21 mutant
protein, which has an internal deletion of 18 amino acids.
3.2. Mitochondrial import and stability after in vitro
synthesis
The cell-free transcription–translation assay of human
PCCA cDNA cloned in the pGEM vector yields a major
radioactive product with a molecular mass of 72 kDa on
SDS-PAGE, as predicted for the precursor a-PCC protein,
and which can be efficiently imported into rat liver mito-
chondria and processed to the mature form [20].
The different PCCA mutations described above were
analyzed for mitochondrial import and stability after in vitro
synthesis. G668R was not assayed as its major pathogenic
effect is clearly a defect in biotynilation and M373K has
already been analyzed by this method [20]. The remaining
mutant proteins were synthesized, imported into mitochon-
dria and converted into the mature form with comparable
Table 1
PCC activities in PCCA-deficient fibroblasts transfected with wild-type or
mutant PCCA constructs
Transfected
construct(s)
PCC activity
(pmol/min/mg protein)
Relative PCC
activitya (%)
pRC/CMV 31.1F10.4 –
pCMV-PCCA 580.8F 171.4 –
pCMV-PCCA+
pCMV-PCCB
3432F 232.9 100
pCMV-PCCB+pCMV-PCCA with mutations:
A75P 917.5F 53 26.7
R77P 125F 26.9 3.6
A138T 322.3F 37.1 9.4
I164T 544.7F 70.2 15.8
M229K 96.5F 34.6 2.8
D368G 148.6F 32 4.3
M373K 122.5F 55.9 3.5
G379V 185F 7.1 5.4
G631R 113.5F 27.6 3.3
G668R 48F 5.7 1.4
delEx21 36.3F 13.5 1.0
Control
transformed
fibroblasts
1123F 455 –
The data show the meanF S.D. from at least two independent experiments.
a Residual activity relative to that obtained with cotransfection with
wild-type PCCA and PCCB constructs.
Fig. 1. Detection of biotinylated proteins in mitochondrial extracts of PCCA-deficient fibroblasts transfected with wild-type (wt) and mutant constructs. C,
control of non-transfected deficient fibroblasts. PC, pyruvate carboxylase. MCCA, a-subunit of methylcrotonyl-CoA carboxylase.
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efficiency to the normal protein. However, the intramitochon-
drial stability of most mutant proteins was clearly diminished
compared to wild-type protein (Fig. 2). Only the mutant
protein carrying M229K remains stable over the 24-h period;
the rest are degraded more rapidly than the wild-type protein.
This effect is very pronounced for A75P. Results from a
representative experiment are shown in Fig. 2B.
4. Discussion
4.1. Functional effect of PCCA mutations
We have used a transformed deficient cell line to
investigate the effect of mutations in the PCCA gene.
The use of transformed cells was necessary to generate
sufficient quantity of cells for repeated expression assays.
We have shown that it is possible to complement the
enzyme defect by transfecting with wild-type PCCA
cDNA, as already reported [28]. However, normal levels
of activity were never achieved (only around 50%). This
limitation was overcome by cotransfection with wild-type
PCCB cDNA, which resulted in 3- to 4-fold higher PCC
activity than in control transformed fibroblasts. The over-
expression of only one subunit probably interferes with the
overall assembly and activity of the PCC complex, which
may depend on a critical stoichiometric balance between
the two subunits, as has been argued for other enzymatic
complexes [21].
To prove that the mutations identified in patients within
the PCCA coding sequence are responsible for the PCC
deficiency, we introduced the mutations in the cDNA
cloned in a pCMV expression vector and tested them in
a transient expression system. All normal and mutant
cDNAs produced significant levels of biotinylated proteins
(except mutant G668R, defective in biotinylation), al-
though the enzymatic activity was partially or severely
diminished.
The crystallized E. coli biotin carboxylase subunit of
acetyl-CoA carboxylase and both the E. coli BCCP protein
and the 1.3 S subunit of P. shermanii transcarboxylase were
used as models to study the structural effect of the PCCA
mutations (Figs. 3 and 4). All mutated residues are well
conserved in homologous proteins. Biotin carboxylase be-
longs to a large family of proteins characterized by an ATP-
grasp fold [29]. The residues involved in PCCA mutations
Fig. 2. Analysis of the intramitochondrial stability of wild-type and mutant PCCA proteins after in vitro synthesis and import into rat liver mitochondria. (A)
Semilogarithmic plot of the mitochondrial degradation time courses of wild-type and mutant PCCA proteins. Labelled PCCA protein was quantitated by laser
densitometry after SDS-PAGE and fluorography and the amount of residual mature PCCA expressed in percentages of the amount of imported protein in the
sample at time 0. The results represent the mean from at least two experiments. (B) SDS-PAGE analysis of labelled wild-type and mutant PCCA protein
turnover in mitochondria in a representative experiment. P, in vitro synthesized PCCA precursor before mitochondrial import.
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mapping to this domain were all found to cluster together in
the three-dimensional structure, with the exception of
M229K (Fig. 3). Residue M229 forms part of a hydrophobic
pocket well conserved in all biotin carboxylases and in
related structures, namely D-Ala:D-Ala ligase and gluta-
thione synthase [30], which is involved in the interaction
with the adenine moiety of the ATP. M229 lies within
approximately 4.5 A˚ of the ATP [13]. It has been suggested
that the substitution for Lys destabilizes the pocket and
reduces ATP binding, although the protein is stable and
binds biotin, as shown in patients’ fibroblasts [27]. The
remaining biotin carboxylase domain PCCA mutations
(A75P, R77W, A138T, I164T, D368G M373K and
G379V) map in close proximity in the crystalline structure
(Fig. 3), clearly defining a region probably important for
function and/or stability of the a subunit. This region lies
exactly opposite away from the active site, which was
defined after modelling the relative positions of bound
biotin and ATP in E. coli biotin carboxylase [13]. A direct
effect on catalysis is therefore unlikely, and the mutations
are most likely affecting the structure of the protein. This
structural alteration may affect the active site, but in vivo,
the abnormally folded proteins are probably recognized and
rapidly degraded as has been described in other diseases
[31]. This is consistent with the fact that no protein is
detected in patient’s cells and with the observed accelerated
mutant protein turnover after in vitro synthesis and mito-
chondrial import. Only after overexpression of the proteins
in the transfection experiments is it possible to detect the
biotinylated mutant proteins in levels comparable to wild-
type protein. These results confirm that the folding of the
biotin carboxylase domain does not influence the biotiny-
lation reaction. In fact, most of the PCCA protein does not
seem to play a role in this, as the C-terminal 67 residues
alone can act as a substrate for biotinylation by the BirA
protein of E. coli [12]. However, in the expression experi-
ments, the correctly biotinylated mutant proteins are defec-
tive in enzymatic activity. The defect in folding/structure
could also be affecting the normal assembly with the h-
subunit to produce a functional PCC oligomer. The putative
folding defects may be analyzed by transient transfection of
cells grown at lower temperature, improving folding and
thus allowing to measure the effect (if any) of the mutations
on the catalytic activity. This interesting experimental
approach has been reported for several disease-causing
mutations [32].
Fig. 3. Modelling of the PCCA biotin carboxylase domain against the E. coli biotin carboxylase subunit of acetyl-CoA carboxylase complexed with ATP (PDB
accession number 1DV2). The PCCA missense mutations found in the biotin carboxylase domain are positioned by alignment with the E. coli sequence where
the normal residues are displayed as red ball and stick structures.
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Mutations G631R and G668R as well as delEx21 map to
the biotinylation domain (Fig. 4). No biotinylated protein
nor residual activity is detectable with the G668R mutation.
It is highly probable that the protein is unstable, as in BCCP
it has been described that the apoenzyme is less stable than
the holoenzyme, and that biotin binding induces a confor-
mational change resulting in increased protease resistance
[33]. Both the deletion of exon 21 which eliminates beta
strands h1 and h2, and mutation G631R, are compatible
with a normal biotinylation of the PCCA protein, as seen in
the expression studies, although the mutant proteins are
inactive. Residue G631 is very well conserved in acetyl-
CoA carboxylases from different species and in related
structures corresponding to lipoyl domains of pyruvate
dehydrogenase, glycine decarboxylase and 2-oxoglutarate
dehydrogenase from different species. Both G631R and
delEx21 result in proteins with an accelerated turnover in
rat liver mitochondria after in vitro synthesis, which may
also be the main molecular effect in the patient’s cells.
4.2. Genotype–phenotype correlations
The clinical spectrum of PCC deficiency is extremely
broad, and, in the case of PCCA-deficient patients, the
establishment of genotype–phenotype correlations is ham-
pered by the extensive genetic heterogeneity and by the fact
that most patients are compound heterozygotes (Table 2).
M373K and G631R changes are present in homozygous
patients presenting a severe phenotype. This is in accordance
with the expression assays where they exhibit null activity
and accelerated protein turnover. The mild phenotype of the
patients with A138T (homozygous) and I164T (hemyzy-
gous, with a frameshift mutation on the second allele) is also
in agreement with the partial residual activity recovered after
transient expression (9% and 16%, respectively). Although
steady-state protein is undetectable in patients’ fibroblasts,
newly synthesized or residual protein with partial activity
could contribute to the milder phenotypic expression of the
disease. This may also be the case of A75P, associated with
26.7% residual activity, but which in contrast is the least
stable after mitochondrial import in the cell-free system (Fig.
2). A75P is present in a heterozygous patient, with a
moderate psychomotor delay. In this case, the contribution
of each mutant allele (A75P and G379V) to the phenotype is
difficult to evaluate.
The skipping of exon 21 in the mRNA produces an in-
frame deletion of 18 amino acids (616–634) in the PCCA
protein. Expression of the cDNA with the corresponding
Fig. 4. Modelling of the PCC biotinylation domain against the E. coli
BCCP of acetyl-CoA carboxylase (PDB accession number 1BDO). PCCA
mutations are identified by alignment and normal residues involved are
represented as red ball and stick structures.
Table 2
Genotypes, clinical presentation and biotinylation status of aPCC subunit of PA patients bearing PCCA mutations expressed in this work
Patient Genotype Clinical
presentation
Percentage PCC
activity in patients’
fibroblasts
Biotinylated
aPCC subunit
in fibroblasts
Reference
3131 (BE) A75P/G379V Moderate no data No [27]
SAG R77W/delEx21 Mild 3.5 Yesa [9]
JMMO A138T/A138T Mild 4 No [9]
ESG I164T/S147fs Mild 4 No [9]
2967 (AG) M229K/ND Mild 0.6b Yes [27]
3144 (NM) D368G/delEx20-21 Severe 2 No [27]
JN M373K/M373K Severe 2 No [20]
MSH delEx21/delEx21 Moderate 1.3 No [9]
DFH, JCS, TC G631R/G631R Severe V 1 No [9]; this work
3135 G668R/delEx22 Severe no data No [27]
Mild: patient alive with near-normal development. Moderate: Patient alive with moderate psychomotor delay. Severe: patient dead or severely retarded.
a Yes: faint band of aPCC of normal size.
b PCC activity measured in patient’s leukocytes.
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deletion produces a protein devoid of enzymatic activity and
rapidly degraded intramitochondrially. However, patient
MSH, homozygous for this change, presents a moderate
phenotype. In this patient, the genomic lesion is a short
deletion (four nucleotides) in position + 3 in the 5Vsplicing
donor site. Although a standard RT-PCR did not detect the
presence of a correctly spliced transcript [22], this cannot be
excluded as the invariant GT is conserved and the Shapiro
splicing score is reduced to only 75%. Real-time PCR
experiments and/or in vitro splicing analysis with minigenes
could be employed to study this possibility, which could
explain a less severe phenotypic expression in patients.
Patient AG with a mild phenotype carries mutation
M229K and a yet unidentified mutation not expressed in
the cDNA on the second allele, so the patient can be
considered hemizygous (M229K plus a functionally ‘‘null’’
allele). M229K mutant protein is the only one of our series
that is stable after import to mitochondria (Fig. 2), which is
consistent with the detection of normal amounts of biotiny-
lated protein in patients’ cells. However, no residual activity
is detectable in the PCC assay, which does not allow the
analysis of the affinity for ATP.
In summary, the high genetic heterogeneity in the pcca
gene defies the drawing of simplistic conclusions on the ge-
notype–phenotype correlations. The characterization of
other mutations, newly identified as more patients are ana-
lyzed, is necessary to get a deeper understanding on the
structure and function of PCC and the relationship to disease
phenotype.
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